Early real-world effectiveness of ustekinumab for Crohn's disease.

Richard James HarrisMartin McDonnellDavid YoungMarion BetteyLouise DowneyLucinda PigottRichard FelwickMarkus GwiggnerJ R Fraser Cummings

Published in: Frontline gastroenterology (2019)

Ustekinumab was well tolerated in a complex UK CD population and demonstrated benefit to patients in terms of clinical response and improvement of biomarkers and with some patients attaining clinical remission. No unexpected safety signals were seen.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
prognostic factors
systematic review
systemic lupus erythematosus
cross sectional